Previous studies (4) have identified specific biomarkers for cancer immunotherapeutic responsiveness, including tumor PD-L1 expression levels (5), DNA mismatch-repair deficiency (6), tumor mutation burden (TMB) (7), and tumor-infiltrating lymphocytes (TILs) levels (8). The gene discussed is CD274; the disease is neoplasm.